Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

C4 Therapeutics (CCCC) EBT Margin (2019 - 2025)

C4 Therapeutics' EBT Margin history spans 7 years, with the latest figure at 184.87% for Q4 2025.

  • For Q4 2025, EBT Margin rose 48042.0% year-over-year to 184.87%; the TTM value through Dec 2025 reached 291.74%, up 385.0%, while the annual FY2025 figure was 291.74%, 385.0% up from the prior year.
  • EBT Margin reached 184.87% in Q4 2025 per CCCC's latest filing, up from 286.43% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 77.99% in Q4 2021 to a low of 1348.42% in Q2 2023.
  • Average EBT Margin over 5 years is 498.77%, with a median of 327.03% recorded in 2021.
  • Peak YoY movement for EBT Margin: tumbled -122492bps in 2022, then soared 120086bps in 2024.
  • A 5-year view of EBT Margin shows it stood at 77.99% in 2021, then plummeted by -1571bps to 1302.91% in 2022, then increased by 19bps to 1057.25% in 2023, then surged by 37bps to 665.29% in 2024, then skyrocketed by 72bps to 184.87% in 2025.
  • Per Business Quant, the three most recent readings for CCCC's EBT Margin are 184.87% (Q4 2025), 286.43% (Q3 2025), and 402.6% (Q2 2025).